He is sponsored as an endorsing performing artist by Conn-Selmer, Inc. Mr. Buselli graduated from Berklee School of music in Boston and received his MM in Jazz studies from Indiana University. While ...

The mining magnate is the chairman of his new party, Trumpet of Patriots, which will run on Trump-inspired policies and aims to sway voters away from the major parties as well as the Greens and teals.

An Australian billionaire who launched a rebranded political party “heavily inspired” by President Donald Trump claimed 10,000 people signed up to join his “Trumpet of Patriots” party on ...

Billionaire Clive Palmer has fashioned himself as a kingmaker, believing he can bankroll his new Trumpet of Patriots candidates into parliament and influence the election through preferences.

Dr. John Baptiste McClellan III’s instruments were a scalpel and his trumpet. The orthopedic surgeon loved to play for staff and patients in hospital hallways, especially around Christmas.

Loading So excited was Palmer that he stumbled over the brave new name and called it, briefly, Trumpet of Parrots. Which, spookily, sounded perfectly apt. We can barely wait to see Palmer ...

Mr Palmer announced on Wednesday that he had joined the largely unknown micro party, which was reportedly first registered with the AEC in 2011, after his attempts to re-register the United ...

In what could be Mr Palmer’s final chance to spend big on Australian politics due to strict new donation and spending caps coming into effect in 2026, it is expected Trumpet of the Patriots will ...

Yes, it is. Last week, we learned that Palmer is to re-enter the fray, astride a new and gleaming steed, an existing political party of his recent acquisition called "Trumpet of Patriots".

It comes after Mr Palmer's previous party, United Australia (UAP), lost its High Court bid to re-register ahead of the federal election. UAP was voluntarily deregistered after the 2022 federal ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).